liquidia technologies inc (NASDAQ:LQDA) Q2 2020 Earnings Conference Call - Final Transcript

Aug 10, 2020 • 04:30 pm ET


liquidia technologies inc (NASDAQ:LQDA) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good afternoon, ladies and gentlemen. My name is Christy, and I will be your conference operator today. I would like to welcome everyone to the Liquidia Technologies Second Quarter 2020 Financial Results and Corporate Update Conference Call. [Operator Instructions]

And I will now hand the call over to Jason Adair, Vice President, Corporate Development and Strategy.

Jason Adair

Thank you, Christy, and good afternoon, everyone. Welcome to Liquidia's Second Quarter 2020 financial results and corporate update conference call.

Today's call will include forward-looking statements pursuant to the Private Securities Litigation Reform Act of 1995 based on current expectations. Such statements represent management's judgment as of today and may involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Liquidia's filings with the SEC, which are available from the SEC at or from Liquidia's website at For information concerning risk factors that could cause such differences that otherwise affect the Company.

I would now like to turn the call over to Neal Fowler, CEO of Liquidia.

Neal Fowler

Good afternoon and thank you for joining us. On the call with me today are Rich Katz, our Chief Financial Officer, Tushar Shah, our Chief Medical Officer who joined us in May, as well as other senior members of Company who are available to answer questions, if needed.

Before Rich and I jumped into describing our accomplishments from the second quarter, I wanted to express how excited I am to have Tushar joining our team at a pivotal moment in our Company's evolution. Transitioning from Teva Pharmaceuticals as Head of Global Specialty Clinical Development, Tushar brings nearly three decades of clinical development experience across respiratory, immunology and neurology. It's quite clear that he shares our passion for improving patient's lives. We are excited to have a support and helping drive the approval of our products and strengthening our pipeline in the years to come. So, welcome again, Tushar.

Like most of the countries the second quarter of 2020 found our team adjusting to a new way of living and working under the threat of a global pandemic. We quickly adapted and continued to build on the momentum from last quarter as we strengthened the Company's portfolio, leadership and balance sheet. We had a strong start to the quarter with the FDA's acceptance of the LIQ861 NDA.

As a reminder, LIQ861 is inhaled dry powder formulation of treprostinil. A prostacyclin analog used to treat pulmonary arterial hypertension or PAH by targeting the pulmonary arteries. We believe that LIQ861 has the potential to maximize the therapeutic benefits of treprostinil by safely delivering higher doses directly into the lungs, using a convenient palm-sized dry powder inhaler.

Our team is well prepared to support the agency's review which from our point of view has not been greatly impacting during this pandemic. With a November 24 PDUFA goal date on the horizon, we will provide relevant updates when needed, but for now all eyes are focused on the end of the year